Stryker (NYSE:SYK) was upgraded by stock analysts at BMO Capital Markets to a “market perform” rating in a research note issued to investors on Tuesday, The Fly reports. The brokerage presently has a $163.00 price objective on the medical technology company’s stock. BMO Capital Markets’ price target indicates a potential upside of 6.74% from the stock’s current price.

A number of other equities research analysts also recently weighed in on SYK. Needham & Company LLC reiterated a “hold” rating on shares of Stryker in a research note on Thursday, December 7th. Royal Bank of Canada reiterated a “buy” rating and set a $155.00 price target on shares of Stryker in a research note on Monday, October 2nd. BidaskClub upgraded shares of Stryker from a “hold” rating to a “buy” rating in a research note on Thursday, August 17th. SunTrust Banks reiterated a “buy” rating and set a $161.00 price target on shares of Stryker in a research note on Monday, October 2nd. Finally, Oppenheimer set a $156.00 price target on shares of Stryker and gave the stock a “hold” rating in a research note on Monday, October 30th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and thirteen have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $153.19.

Shares of Stryker (NYSE SYK) traded up $0.78 during mid-day trading on Tuesday, reaching $152.71. 826,100 shares of the company were exchanged, compared to its average volume of 1,177,418. Stryker has a fifty-two week low of $116.27 and a fifty-two week high of $160.62. The company has a market capitalization of $56,857.92, a price-to-earnings ratio of 24.08, a P/E/G ratio of 2.39 and a beta of 0.78. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.37 and a quick ratio of 1.61.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, October 26th. The medical technology company reported $1.52 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.50 by $0.02. Stryker had a net margin of 14.67% and a return on equity of 24.11%. The business had revenue of $3.01 billion for the quarter, compared to analyst estimates of $2.97 billion. During the same quarter in the previous year, the firm posted $1.39 earnings per share. Stryker’s revenue was up 6.1% compared to the same quarter last year. equities analysts anticipate that Stryker will post 6.47 EPS for the current fiscal year.

In other news, insider Lonny J. Carpenter sold 5,000 shares of the business’s stock in a transaction on Friday, November 3rd. The shares were sold at an average price of $155.34, for a total value of $776,700.00. Following the sale, the insider now owns 83,207 shares in the company, valued at approximately $12,925,375.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 7.40% of the stock is currently owned by insiders.

Several large investors have recently modified their holdings of SYK. Renaissance Technologies LLC acquired a new position in Stryker during the 1st quarter worth about $948,000. Nomura Asset Management Co. Ltd. lifted its position in Stryker by 201.5% during the 1st quarter. Nomura Asset Management Co. Ltd. now owns 407,978 shares of the medical technology company’s stock worth $53,711,000 after buying an additional 272,680 shares in the last quarter. Bath Savings Trust Co lifted its position in Stryker by 5.1% during the 2nd quarter. Bath Savings Trust Co now owns 71,879 shares of the medical technology company’s stock worth $9,975,000 after buying an additional 3,458 shares in the last quarter. DnB Asset Management AS lifted its position in Stryker by 0.5% during the 2nd quarter. DnB Asset Management AS now owns 36,995 shares of the medical technology company’s stock worth $5,134,000 after buying an additional 200 shares in the last quarter. Finally, Xact Kapitalforvaltning AB lifted its position in Stryker by 0.8% during the 2nd quarter. Xact Kapitalforvaltning AB now owns 52,681 shares of the medical technology company’s stock worth $7,311,000 after buying an additional 427 shares in the last quarter. Institutional investors own 74.97% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was first published by American Banking News and is owned by of American Banking News. If you are accessing this report on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The original version of this report can be read at https://www.americanbankingnews.com/2017/12/12/stryker-syk-raised-to-market-perform-at-bmo-capital-markets.html.

Stryker Company Profile

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

The Fly

Analyst Recommendations for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.